The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 24 hours post dose
Maximum Plasma Concentration (Cmax) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Time of the Maximum Observed Concentration (Tmax) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Concentration at 24 Hours Postdose (C24) of MK-2828 in Plasma
Timeframe: At designated time points up to 24 hours post dose
Apparent Terminal Elimination Half-life (t1/2) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Apparent Total Plasma Clearance (CL/F) of MK-2828
Timeframe: Pre dose and at designated time points up to 192 hours post dose
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of MK-2828 in Plasma
Timeframe: Pre dose and at designated time points up to 192 hours post dose